174 related articles for article (PubMed ID: 22158484)
1. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?
Catena L; Bichisao E; Milione M; Valente M; Platania M; Pusceddu S; Ducceschi M; Zilembo N; Formisano B; Bajetta E
Tumori; 2011; 97(5):564-7. PubMed ID: 22158484
[TBL] [Abstract][Full Text] [Related]
2. [Neuroendocrine Tumors].
Jantze A; Haller C; Delaloye R
Praxis (Bern 1994); 2016 Jan; 105(1):7-12; quiz 13-4. PubMed ID: 26732711
[No Abstract] [Full Text] [Related]
3. Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site.
Berner AM; Pipinikas C; Ryan A; Dibra H; Moghul I; Webster A; Luong TV; Thirlwell C
Neuroendocrinology; 2020; 110(7-8):563-573. PubMed ID: 31658461
[TBL] [Abstract][Full Text] [Related]
4. A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Unknown Primary.
Abdel-Rahman O
Neuroendocrinology; 2021; 111(9):876-882. PubMed ID: 32980845
[TBL] [Abstract][Full Text] [Related]
5. Current concepts in the diagnosis and management of neuroendocrine neoplasms of unknown primary origin.
Alexandraki KI; Tsoli M; Kyriakopoulos G; Angelousi A; Nikolopoulos G; Kolomodi D; Kaltsas GA
Minerva Endocrinol; 2019 Dec; 44(4):378-386. PubMed ID: 30991795
[TBL] [Abstract][Full Text] [Related]
6. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
7. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.
Pavel M; Baudin E; Couvelard A; Krenning E; Öberg K; Steinmüller T; Anlauf M; Wiedenmann B; Salazar R;
Neuroendocrinology; 2012; 95(2):157-76. PubMed ID: 22262022
[No Abstract] [Full Text] [Related]
8. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
9. Management of neuroendocrine tumors of unknown origin.
Polish A; Vergo MT; Agulnik M
J Natl Compr Canc Netw; 2011 Dec; 9(12):1397-402; quiz 1403. PubMed ID: 22157557
[TBL] [Abstract][Full Text] [Related]
10. Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease.
Matrood S; Apostolidis L; Schrader J; Krug S; Lahner H; Ramaswamy A; Librizzi D; Kender Z; Kröcher A; Kreutzfeldt S; Gress TM; Rinke A
Front Endocrinol (Lausanne); 2021; 12():709256. PubMed ID: 34690926
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
[TBL] [Abstract][Full Text] [Related]
13. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
Saller JJ; Haider M; Al-Diffalha S; Coppola D
Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
[TBL] [Abstract][Full Text] [Related]
14. Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms.
Lim KHJ; Raja H; D'Arienzo P; Barriuso J; McNamara MG; Hubner RA; Mansoor W; Valle JW; Lamarca A
Neuroendocrinology; 2020; 110(7-8):688-696. PubMed ID: 31639796
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic neuroendocrine neoplasms.
Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
[TBL] [Abstract][Full Text] [Related]
17. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.
Fisher MD; Pulgar S; Kulke MH; Mirakhur B; Miller PJ; Walker MS; Schwartzberg LS
J Gastrointest Cancer; 2019 Dec; 50(4):816-823. PubMed ID: 30121904
[TBL] [Abstract][Full Text] [Related]
19. [[Radioguided surgery in the treatment of gastro-entero-pancreatic neuroendocrine tumors] ].
Cirillo F; Bottini A; Lima G; Alquati P
Minerva Chir; 2000; 55(7-8):517-21. PubMed ID: 11140106
[TBL] [Abstract][Full Text] [Related]
20. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
